DYX Diasys Corp

DiaSys Corporation (AMEX:DYX), a global healthcare products company, has announced a net loss of $2,029,245 $(.12) per share on net sales of $1,914,077 for its fiscal year ended June 30, 2005. For the fiscal year ending June 30, 2004, the company had a net loss of $2,985,726 $(.23) per share on net sales of $1,862,612. The reason for the late filing is that The Company has been unable to complete compilation of all necessary information due to the unexpected travel schedule and other responsibilities of its President/Chief Financial Officer and the complexities of compliance with the Sarbanes-Oxley Act. The Company expects to complete all necessary functions to effect filing of its Annual Report on Form 10-KSB by Wednesday, October 19, 2005. DiaSys Corporation designs, develops, manufactures and distributes proprietary medical laboratory equipment, consumables and infectious disease test-kits to healthcare & veterinary laboratories worldwide. Headquartered in Waterbury, Connecticut USA, the Company operates in Europe through its wholly owned subsidiary based in Wokingham, England and in Pacific Asia through its strategic business partner located in Guangzhou, China. DiaSys, Parasep and Urisep are registered trademarks of DiaSys Corporation. This press release contains forward-looking statements within the meaning of, and made pursuant to, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company or events, or timing of events, relating to the Company to materially differ from those expressed or implied by such forward looking statements. DiaSys refers interested parties to its most recent Annual Report on Form 10-KSB and other SEC filings for a complete description of, and discussions about, the Company.